Report cover image

Latin America Migraine Drugs Market 2023-2027

Publisher TechNavio
Published Nov 10, 2022
Length 120 Pages
SKU # INF17509674

Description

Global Migraine Drugs Market In Latin America 2023-2027

Technavio has been monitoring the migraine drugs market in Latin America and it is poised to grow by $82.31 mn during 2023-2027, accelerating at a CAGR of 5.82% during the forecast period. Our report on the migraine drugs market in Latin America provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current regional market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of migraine in Latin America, the growing number of migraine treatment awareness programs, and drug reformulations.

Technavio's migraine drugs market in Latin America is segmented as below:

By End-user
  • Hospital
  • Retail
  • Online
This study identifies the introduction of new classes of drugs with higher clinical efficacy as one of the prime reasons driving the migraine drugs market in Latin America's growth during the next few years. Also, the rise in the popularity of devices for migraine treatment and rising advances in migraine drugs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters. Our report on the migraine drugs market in Latin America covers the following areas:
  • Migraine drugs market sizing in Latin America
  • Migraine drugs market forecast in Latin America
  • Migraine drugs market industry analysis in Latin America
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading migraine drugs markets in Latin America vendors that include AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Bausch Health Co. Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Ethypharm SAS, GlaxoSmithKline Plc, H Lundbeck AS, IntelGenx Technologies Corp., Klaria Pharma Holding AB, Kowa Co. Ltd., OptiNose Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the migraine drugs market in Latin America analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

120 Pages
    • Market overview
    • Market ecosystem
    • Market definition
    • Market segment analysis
    • Market size 2022
    • Market outlook: Forecast for 2022-2027
    • Migraine Drugs Market in Latin America 2017 - 2021
    • Therapy Segment Analysis 2017 - 2021
    • End-User Segment Analysis 2017 - 2021
    • Country Segment Analysis 2017 - 2021
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
    • Market segments
    • Comparison by Therapy
    • Preventive treatment - Market size and forecast 2022- 2027
    • Abortive treatment - Market size and forecast 2022-2027
    • Market opportunity by Therapy
    • Market segments
    • Comparison by End-user
    • Hospital - Market size and forecast 2022-2027
    • Retail - Market size and forecast 2022-2027
    • Online - Market size and forecast 2022-2027
    • Market opportunity by End-user
    • Customer landscape overview
    • Geographic segmentation
    • Geographic comparison
    • Mexico - Market size and forecast 2022-2027
    • Brazil - Market size and forecast 2022-2027
    • Argentina - Market size and forecast 2022-2027
    • Chile - Market size and forecast 2022-2027
    • Rest of Latin America - Market size and forecast 2022- 2027
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Impact of drivers and challenges
    • Market trends
    • Overview
    • Vendor landscape
    • Landscape disruption
    • Industry risks
    • Vendors covered
    • Market positioning of vendors
    • AbbVie Inc.
    • Amgen Inc.
    • Amneal Pharmaceuticals Inc.
    • Bayer AG
    • Daiichi Sankyo Co. Ltd.
    • Eli Lilly and Co.
    • Endo International Plc
    • GlaxoSmithKline Plc
    • H Lundbeck AS
    • IntelGenx Technologies Corp.
    • Klaria Pharma Holding AB
    • Kowa Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
    • Scope of the report
    • Inclusions and exclusions checklist
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us